Therapeutic effect of aerobic training on bone remodeling markers in sedentary cigarette males

Abstract Osteoporosis results from an imbalance in bone remodeling, which is known to follow a circadian rhythm determined by a functional relationship between intestine and bone tissue. Specific intestinal peptides have been identified as mediators. Glucagon-like peptide 1 and glucagon-like peptide 2, have been associated with bone health. Our main objective was to determine whether postprandial plasma levels of glucagon-like peptide 1, glucagon-like peptide 2 and dipeptidyl-peptidase 4 activity, are associated with osteoporosis in non-diabetic postmenopausal women. We studied non-diabetic postmenopausal women with osteoporosis diagnosed by dual-energy X-ray absorptiometry (cases, n = 43) and age-matched (±1 yr) controls without osteoporosis or a history of osteoporotic fracture (n = 43). We measured postprandial plasma levels of glucagon-like peptide 1, glucagon-like peptide 2, and dipeptidyl-peptidase 4 activity, bone mineral density, and baseline levels of bone remodeling markers and analyzed the food intake using a food-frequency questionnaire. Postprandial glucagon-like peptide 1 values were lower (p < 0.001) in cases, μ (SEM) = 116.25 (2.68), than in controls, μ (SEM) = 126.79 (2.68). Glucagon-like peptide 1 was associated with reduced osteoporosis risk in the crude logistic regression analysis [OR (95% CI) = 0.724 (0.53–0.97), p = 0.031] and adjusted analysis [OR = 0.603 (0.38–0.94), p = 0.027]. We found no association of glucagon-like peptide 2, or dipeptidyl-peptidase 4 activity with osteoporosis. Postprandial glucagon-like peptide 1 levels are related to osteoporosis and osteoporosis risk in non-diabetic postmenopausal women. Further studies are required to verify these findings.

Download Full-text

Prediction of Bone Mass Density Variation by Bone Remodeling Markers in Postmenopausal Women with Vitamin D Insufficiency Treated with Calcium and Vitamin D Supplementation

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2002-021968 ◽

2003 ◽

Vol 88 (11) ◽

pp. 5175-5179 ◽

Cited By ~ 49

Author(s):

Franck Grados ◽

Michel Brazier ◽

Saïd Kamel ◽

Marc Mathieu ◽

Nathalie Hurtebize ◽

...

Keyword(s):

Vitamin D ◽

Bone Remodeling ◽

Elderly Women ◽

Vitamin D Insufficiency ◽

Vitamin D Supplementation ◽

Hydroxyvitamin D ◽

Bone Remodeling Markers ◽

25 Hydroxyvitamin D ◽

Total Body

Abstract The aim of this study was to determine whether early changes in bone markers could predict long-term response in bone mineral density (BMD) after calcium (500 mg) and vitamin D (400 IU) supplementation twice daily in ambulatory elderly women with vitamin D insufficiency (25-hydroxyvitamin D, <12 ng/ml). One hundred and ninety-two women (mean age, 75 ± 7 yr) were randomized to receive either the supplementation (n = 95) or a placebo (n = 97) in a double-blind, controlled clinical trial for 1 yr. In comparison with the placebo group, supplementation significantly increased BMD, normalized 25-hydroxyvitamin D and significantly decreased intact PTH and bone remodeling markers. The initial values of telopeptide cross-links were correlated with improvement in total body BMD [urinary N-telopeptides (NTX), r = 0.38; C-telopeptides (CTX), r = 0.32; serum CTX, r = 0.28], and the 3-month changes in the same markers were correlated with improvement in total body (urinary N-telopeptides, r = −0.29; serum CTX, r = −0.26) and vertebral BMD (CTX, r = −0.26; all P < 0.05). We concluded that short-term changes in bone resorption markers can predict long-term variations in BMD in elderly women with vitamin D insufficiency receiving calcium and vitamin D supplementation.

Download Full-text

Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer

Journal of Pharmaceutical and Biomedical Analysis ◽

10.1016/j.jpba.2004.10.007 ◽

2005 ◽

Vol 37 (1) ◽

pp. 171-176 ◽

Cited By ~ 18

Author(s):

Dimitrios Pectasides ◽

Dimitrios Farmakis ◽

Maria Nikolaou ◽

Ioannis Kanakis ◽

Vassiliki Kostopoulou ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Bone Remodeling ◽

Diagnostic Value ◽

Bone Remodeling Markers

Download Full-text

Bone remodeling markers: Assessment of fracture risk and fracture risk reduction

Current Osteoporosis Reports ◽

10.1007/bf02686912 ◽

2003 ◽

Vol 1 (3) ◽

pp. 91-97 ◽

Cited By ~ 1

Author(s):

Aubrey Blumsohn

Keyword(s):

Fracture Risk ◽

Risk Reduction ◽

Bone Remodeling ◽

Bone Remodeling Markers ◽

Fracture Risk Reduction

Download Full-text

BONE REMODELING MARKERS AS PREDICTORS OF BONE METABOLIC CHANGES IN MALES WITH DIABETIC OSTEOPATHY

Rheumatology Science and Practice ◽

10.14412/1995-4484-2020-290-293 ◽

2020 ◽

Vol 58 (3) ◽

pp. 290-293

Author(s):

S. S. Safarova ◽

S. S. Safarova

Keyword(s):

Vitamin D ◽

Vitamin D Deficiency ◽

Bone Remodeling ◽

Control Group ◽

Mineral Density ◽

Amino Terminal ◽

Bone Remodeling Markers ◽

History Of ◽

Male Patients

Diabetic osteopathy is one of the little studied complications of diabetes mellitus (DM), which leads to common lowtrauma fractures and, as a consequence, disability and death. The level of insulin is connected with bone functional and morphological changes followed by decreased bone mineral density (BMD) in the early stages of diabetic osteopathy. Objective: to study bone morphofunctional properties in males with type 1 and 2 DM (T1DM and T2DM). Subjects and methods. Examinations were made in 41 male patients with T1DM and 52 male patients with T2DM without a history of fractures. Their age varied from 40 to 70 years (mean age, 55.8±0.7 years and 58.4±0.9 years, respectively). A control group consisted of 34 patients (mean age, 55.9±0.9 years) without a history of DM. Patients with other endocrine disorders, end-stage complications, or chronic liver and kidney diseases were excluded from the investigation. BMD was determined by dual-energy X-ray absorptiometry (DXA). Serum bone remodeling markers (procollagen type 1 amino-terminal propeptide and C-terminal telopeptide), as well as 25(OH)D, parathyrin, insulin, glycated hemoglobin (HbA1c), and electrolytes (Ca2+, P+) were evaluated. Results and discussion. An association of BMD with renal function, HbA1c, and body mass index was observed in patients with T2DM. In the T1MD group, BMD was closely related to insulin deficiency and was significantly lower than that in the control group. In patients with vitamin D deficiency, BMD was significantly lower than in those with normal vitamin D levels (p<0.05). The patients with T1DM displayed both a decrease in BMD (p<0.05) and a pronounced change in the levels of bone markers (p<0.05). Those with T2DM had impaired bone remodeling processes, which was determined by the level of these markers (p<0.05) and observed in the presence of normal BMD due to the complex pathophysiology of the underlying disease. Conclusion. Vitamin D deficiency, insufficient and decreased insulin sensitivity, hyperglycemia, and overweight are important causes of osteopathy in patients with DM. The markers of bone remodeling may become promising indicators for diagnosing osteopathy, but additional studies are needed to elaborate recommendations for their use in routine practice in order to predict and prevent this complication of DM.

Download Full-text

GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia

Journal of Endocrinology ◽

10.1530/joe-11-0015 ◽

2011 ◽

Vol 209 (2) ◽

pp. 203-210 ◽

Cited By ~ 48

Author(s):

Bernardo Nuche-Berenguer ◽

Daniel Lozano ◽

Irene Gutiérrez-Rojas ◽

Paola Moreno ◽

María L Mariñoso ◽

...

Keyword(s):

Bone Mass ◽

Bone Remodeling ◽

Lipid Lowering ◽

Saline Control ◽

Protein Isolation ◽

Bone Remodeling Markers ◽

Receptor Activator ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Vertebral Bone Mass

Increased fat mass contributes to bone deterioration. Glucagon-like peptide 1 (GLP-1) and its related peptide exendin 1–39 amide (Ex-4), two lipid-lowering peptides, exert osteogenic effects in diabetic states. We examined the actions of 3-day administration of GLP-1 or Ex-4 on bone remodeling markers and on bone mass and structure in hyperlipidic (HL) and hypercaloric rats. Wistar rats on a hyperlipidemic diet for 35 days were subcutaneously administered GLP-1 (0.86 nmol/kg per h), Ex-4 (0.1 nmol/kg per h), or saline (control) by continuous infusion for 3 days. After killing, tibiae were removed for total RNA and protein isolation, as well as femurs and L1–L4 vertebrae for bone mass and quality assessment. Body weight and plasma insulin were unaltered in HL rats, which showed osteopenia (by dual-energy X-ray absorptiometry), associated with hyperglycemia, hypertriglyceridemia, and hypercholesterolemia. GLP-1 or Ex-4 administration decreased the levels of glucose, triglycerides, and total cholesterol in plasma but increased osteocalcin (OC) gene expression and the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) ratio – at the expense of an augmented OPG – above corresponding control values in the tibia. Each tested peptide similarly reversed the decreased femoral and vertebral bone mass in these rats, whereas the deteriorated trabecular structure in the vertebrae improved associated with normalization of bone remodeling. These findings demonstrate that GLP-1 and Ex-4 are similarly efficient in reversing the bone alterations in this HL rat model, which has proven to be useful for studying the fat–bone relationships.

Download Full-text